Sponsors (20)
The bill aims to strengthen U.S. medical supply resilience, speed access, and boost U.S. firms by building trusted trade partnerships and harmonizing rules, but it does so at the risk of higher costs, potential safety and privacy trade-offs, and increased trade or political friction.
Hospitals and patients (including those with chronic conditions) would face fewer drug and medical product shortages because the bill diversifies suppliers, prioritizes reliable partners, and speeds emergency imports.
U.S. medical manufacturers, researchers, and small businesses could gain expanded export and procurement opportunities, clearer rules for trusted partners, and more predictable supply chains through investment incentives, market access, and R&D cooperation.
Federal national security is strengthened for taxpayers by reducing reliance on potentially unreliable foreign suppliers, protecting key technology/intellectual property, and working with trusted trade partners for critical medical goods.
Hospitals, taxpayers, and health systems could face higher costs if diversifying, reshoring, or favoring 'trusted' partners requires more expensive domestic or allied sourcing or government subsidies.
The bill could provoke diplomatic friction or trade retaliation that raises prices or disrupts supply chains for U.S. consumers, businesses, and taxpayers.
Faster cross-border movement and regulatory harmonization risk reducing independent domestic regulatory scrutiny, which could raise safety or quality concerns for patients and hospitals if relied on excessively.
Based on analysis of 7 sections of legislative text.
Introduced March 18, 2025 by Nicole Malliotakis · Last progress March 18, 2025
Authorizes the President to negotiate and enter "trusted trade partner" agreements with other countries that would remove or alter tariffs and trade barriers on medical devices, drugs, and related inputs to strengthen U.S. medical supply chains. The law sets criteria for choosing partners, lists possible agreement features (tariff elimination, supplier diversification, regulatory cooperation, IP protections, procurement access, and emergency exemptions), requires advance notice and regular reporting to Congress, creates a congressional review-and-disapproval window, and tasks the U.S. Trade Representative with ongoing monitoring and recommended remedies for noncompliance.